Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice

Castleman's disease is a lymphoproliferative disorder thought to be related to deregulated production of IL-6. We have previously shown that mice lacking the trans-acting factor C/EBP beta, a transcriptional regulator of IL-6 and a mediator of IL-6 intracellular signaling, develop a pathology nearly identical to multicentric Castleman's disease, together with increasingly high levels of circulating IL-6. We describe here how the simultaneous inactivation of both IL-6 and C/EBP beta genes prevents the development of pathological traits of Castleman's disease observed in C/EBP beta-deficient mice. Histological and phenotypic analysis of lymph nodes and spleen of double mutant mice did not show either the lymphoadenopathy and splenomegaly or the abnormal expansion of myeloid, B and plasma cell compartments observed in C/EBP beta-/- mice, while B cell development, although delayed, was normal. Our data demonstrate that IL-6 is essential for the development of multicentric Castleman's disease in C/EBP beta-/- mice.

[1]  R. Cortese,et al.  Lymphoproliferative disorder and imbalanced T‐helper response in C/EBP beta‐deficient mice. , 1995, The EMBO journal.

[2]  Nobuaki Yoshida,et al.  Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages , 1995, Cell.

[3]  A. Kuramoto,et al.  Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. , 1995, Blood.

[4]  A. Green,et al.  Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes , 1994 .

[5]  A. Green,et al.  Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. , 1994, Blood.

[6]  R. Zinkernagel,et al.  Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.

[7]  B. Klein,et al.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. , 1994, The New England journal of medicine.

[8]  G. Ciliberto,et al.  Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion. , 1994, The EMBO journal.

[9]  B. Peterson,et al.  Multicentric Castleman's disease. , 1993, Seminars in oncology.

[10]  M. Stoffel,et al.  Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. , 1993, Blood.

[11]  R. Cortese,et al.  IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C EBP , 1990, Cell.

[12]  A. Nienhuis,et al.  Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. , 1990, The Journal of clinical investigation.

[13]  S. Akira,et al.  A nuclear factor for IL‐6 expression (NF‐IL6) is a member of a C/EBP family. , 1990, The EMBO journal.

[14]  B. Klein,et al.  Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. , 1989, Blood.

[15]  S. Akira,et al.  Biological and clinical aspects of interleukin 6. , 1990, Immunology today.

[16]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. , 1989, Blood.